+

WO2009041113A1 - CELLULE NK AYANT UN GÈNE DU RÉCEPTEUR Fc INTRODUIT DANS SON GÉNOME, PROCÉDÉ DE PRODUCTION D'UNE TELLE CELLULE ET PROCÉDÉ D'UTILISATION D'UNE TELLE CELLULE POUR LE TEST CYTOTOXICITÉ CELLULAIRE DÉPENDANTE D'ANTICORPS (CCDA) - Google Patents

CELLULE NK AYANT UN GÈNE DU RÉCEPTEUR Fc INTRODUIT DANS SON GÉNOME, PROCÉDÉ DE PRODUCTION D'UNE TELLE CELLULE ET PROCÉDÉ D'UTILISATION D'UNE TELLE CELLULE POUR LE TEST CYTOTOXICITÉ CELLULAIRE DÉPENDANTE D'ANTICORPS (CCDA) Download PDF

Info

Publication number
WO2009041113A1
WO2009041113A1 PCT/JP2008/058670 JP2008058670W WO2009041113A1 WO 2009041113 A1 WO2009041113 A1 WO 2009041113A1 JP 2008058670 W JP2008058670 W JP 2008058670W WO 2009041113 A1 WO2009041113 A1 WO 2009041113A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
same
receptor gene
antibody
assay
Prior art date
Application number
PCT/JP2008/058670
Other languages
English (en)
Japanese (ja)
Inventor
Natsuhiko Sugimura
Yuji Mishima
Kiyohiko Hatake
Original Assignee
Olympus Corporation
Japanese Foundation For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olympus Corporation, Japanese Foundation For Cancer Research filed Critical Olympus Corporation
Priority to JP2009534209A priority Critical patent/JP5282040B2/ja
Publication of WO2009041113A1 publication Critical patent/WO2009041113A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'objectif de l'invention est de produire des cellules effectrices uniformes pour un test CCDA à grande échelle, sans prélever de cellules dans l'organisme d'un volontaire sain ou d'un sujet; de construire un système de test CCDA en utilisant lesdites cellules effectrices. Une souche de cellules effectrices peut être établie, laquelle présente un récepteur Fc exprimé à la surface cellulaire, et peut être cultivée en continu (sous-cultivée). Plus spécifiquement, une souche de cellules issues d'une cellule NK peut être établie, laquelle présente un gène du récepteur Fc intégré dans le chromosome de la cellule à l'aide d'un vecteur viral recombinant.
PCT/JP2008/058670 2007-09-28 2008-05-09 CELLULE NK AYANT UN GÈNE DU RÉCEPTEUR Fc INTRODUIT DANS SON GÉNOME, PROCÉDÉ DE PRODUCTION D'UNE TELLE CELLULE ET PROCÉDÉ D'UTILISATION D'UNE TELLE CELLULE POUR LE TEST CYTOTOXICITÉ CELLULAIRE DÉPENDANTE D'ANTICORPS (CCDA) WO2009041113A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009534209A JP5282040B2 (ja) 2007-09-28 2008-05-09 Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007254099 2007-09-28
JP2007-254099 2007-09-28

Publications (1)

Publication Number Publication Date
WO2009041113A1 true WO2009041113A1 (fr) 2009-04-02

Family

ID=40511014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058670 WO2009041113A1 (fr) 2007-09-28 2008-05-09 CELLULE NK AYANT UN GÈNE DU RÉCEPTEUR Fc INTRODUIT DANS SON GÉNOME, PROCÉDÉ DE PRODUCTION D'UNE TELLE CELLULE ET PROCÉDÉ D'UTILISATION D'UNE TELLE CELLULE POUR LE TEST CYTOTOXICITÉ CELLULAIRE DÉPENDANTE D'ANTICORPS (CCDA)

Country Status (2)

Country Link
JP (1) JP5282040B2 (fr)
WO (1) WO2009041113A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519360A (ja) * 2010-02-11 2013-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ３ｄａｄｃｃｎｋｆａｃｓアッセイ
JP2015223143A (ja) * 2014-05-29 2015-12-14 国立大学法人富山大学 Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法
CN110546265A (zh) * 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
CN112980851A (zh) * 2021-03-03 2021-06-18 上海奥浦迈生物科技股份有限公司 高效检测融合蛋白/抗体Fc段不能介导ADCC和CDC活性的方法
JP2021522839A (ja) * 2018-05-14 2021-09-02 インダプタ セラピューティクス インコーポレイテッド 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット
US12152253B2 (en) 2012-04-18 2024-11-26 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020129838A1 (fr) * 2018-12-17 2020-06-25 株式会社カネカ Procédé de criblage pour cellules produisant un anticorps spécifique d'un antigène spécifique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004147565A (ja) * 2002-10-30 2004-05-27 Japan Science & Technology Agency 不死化ナチュラルキラー細胞株
US20060292156A1 (en) * 2004-07-10 2006-12-28 Campbell Kerry S Genetically modified human natural killer cell lines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159242A0 (en) * 2001-07-06 2004-06-01 Senomyx Inc Expression of functional human olfactory cyclic nucleotide gated (cng) channel in recombinant host cells and use thereof in cell based assays to identify smell modulators
CA2512956A1 (fr) * 2003-01-13 2004-07-29 Emory University Procedes de detection d'une expression genique dans des cellules saines et dans des cellules cancereuses
JP2007053926A (ja) * 2005-08-23 2007-03-08 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai 光毒性の高感度検出方法及び光毒性検出用キット

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004147565A (ja) * 2002-10-30 2004-05-27 Japan Science & Technology Agency 不死化ナチュラルキラー細胞株
US20060292156A1 (en) * 2004-07-10 2006-12-28 Campbell Kerry S Genetically modified human natural killer cell lines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIAO F. ET AL.: "Cross-linking of FcyRIIIA on natural killer cells results in tyrosine phosphorylation of PLC-yl and PLC-y2.", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 7, 1993, pages 2668 - 2674 *
SUCK G. ET AL.: "KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.", EXPERIMENTAL HEMATOLOGY, vol. 33, no. 10, 2005, pages 1160 - 1171, XP005108371, DOI: doi:10.1016/j.exphem.2005.06.024 *
YUJI MISHIMA ET AL.: "Establishment of reproducible ADCC assay system.", 66TH PROCEEDINGS OF THE JAPANESE CANCER ASSOCIATION, vol. 340, 25 August 2007 (2007-08-25), pages 750 *
YUJI MISHIMA: "Kotai Iyaku no Hotai Izonsei, Kotai Izonsei Satsusaibo Koka", PHARMA MEDICA, vol. 25, no. 3, 10 March 2007 (2007-03-10), pages 9 - 13 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519360A (ja) * 2010-02-11 2013-05-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ３ｄａｄｃｃｎｋｆａｃｓアッセイ
US10330669B2 (en) 2010-02-11 2019-06-25 Hoffmann-La Roche Inc. 3D ADCC NK FACS assay
US12152253B2 (en) 2012-04-18 2024-11-26 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
JP2015223143A (ja) * 2014-05-29 2015-12-14 国立大学法人富山大学 Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法
CN110546265A (zh) * 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
JP2020507349A (ja) * 2017-02-09 2020-03-12 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法
US11920156B2 (en) 2017-02-09 2024-03-05 Indapta Therapeutics, Inc. Engineered natural killer (NK) cells and compositions and methods thereof
JP2021522839A (ja) * 2018-05-14 2021-09-02 インダプタ セラピューティクス インコーポレイテッド 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット
CN112980851A (zh) * 2021-03-03 2021-06-18 上海奥浦迈生物科技股份有限公司 高效检测融合蛋白/抗体Fc段不能介导ADCC和CDC活性的方法

Also Published As

Publication number Publication date
JP5282040B2 (ja) 2013-09-04
JPWO2009041113A1 (ja) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2009041113A1 (fr) CELLULE NK AYANT UN GÈNE DU RÉCEPTEUR Fc INTRODUIT DANS SON GÉNOME, PROCÉDÉ DE PRODUCTION D'UNE TELLE CELLULE ET PROCÉDÉ D'UTILISATION D'UNE TELLE CELLULE POUR LE TEST CYTOTOXICITÉ CELLULAIRE DÉPENDANTE D'ANTICORPS (CCDA)
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
WO2006070370A3 (fr) Systemes de culture de cellules souches
WO2009114702A3 (fr) Production recombinante de protéines humaines authentiques utilisant des systèmes d’expression de cellules humaines
WO2010148203A3 (fr) Cellules productrices pour vecteurs rétroviraux compétents en réplication
AU2009209251A8 (en) Stabilized Angiopoietin-2 antibodies and uses thereof
MX2010002990A (es) Produccion de isoprenoides.
EP2808393A3 (fr) Cellules de déficience fucosylation
WO2011116922A9 (fr) Substrat thermoréactif comportant des microgels, procédé de fabrication de ce substrat et procédé de culture de cellules biologiques
WO2008070082A3 (fr) Acides microribonucléiques spécifiques de cellule souche de progéniteur et leurs utilisations
HK1080115A1 (en) Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom e1-
HK1163160A1 (en) Delivering functional nucleic acids to mammalian cells via bacterially- derived, intact minicells
EP2584034B8 (fr) Différenciation de cellules souches pluripotentes en utilisant des cellules nourricières humaines
WO2008033517A3 (fr) Améliorations à la culture de cellules
WO2005080551A3 (fr) Cellules souches
MX2020010461A (es) Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados.
EP4406615A3 (fr) Procédé de production d'une immunoglobuline glycosylée
NZ595476A (en) Plant snf1-related protein kinase gene
NZ607627A (en) Mutated protoporphyrinogen ix oxidase (ppx) genes
WO2005069840A3 (fr) Procedes destines a produire un produit de fermentation
WO2007100845A3 (fr) Cellules souches totipotentes non embryonnaires DE TYPE blastomères et méthodes
WO2016007570A3 (fr) Lymphocytes t tueurs naturels invariants (inkt) génétiquement modifiés procédés de production et d'utilisation de ceux-ci
WO2010111659A8 (fr) Cellules initiatrices de tumeur et procédés pour les utiliser
IL184696A (en) Recombinant expression of vitamin k epoxide reductase subunit 1 to enhance protein expression dependent on vitamin k
WO2000052135A3 (fr) Mise au point de voies de sialylation intracellulaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752553

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009534209

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08752553

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载